number.

-Please type a plus sign (+) inside this box — +

PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032

Pateix and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No. 126881209900

First Inventor or Application Identifier Cha

Charles A. Nicolette

Title

THERAPEUTIC COMPOUNDS FOR OVARIAN CANCER

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Express Mail Label No. | EL 849 465 094 US

	APPLICATION ELEN	MENTS	ADDRESS TO	Assistant C Box Patent	ommissioner for Patents Application				
See MPEP c	hapter 600 concerning design patent ap	pplication contents.	1,122,120						
1.	ee Transmittal Form (e.g., PTO/SE Submit an original and a duplicate for fe pplicant claims small entity status. see 37 CFR 1.27.	B/17) e processing)  I Pages 57 ]  ns & D	Washington, DC 20231  7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper (6pgs)  c. Statements verifying identity of above copies  ACCOMPANYING APPLICATIONS PARTS  9. Assignment Papers (cover sheet & document(s))						
	Abstract of the Disclosure rawing(s) (35 U.S.C.113) [Tota	l Sheets]	10. 37 C.F.R.§3.73(b)Statement Power of (when there is an assignee) Attorney  11. English Translation Document (if applicable)						
5. Oath or I	Declaration [ <i>Total</i> Newly executed (original or copy)	Pages 2							
b. 🔲	Copy from a prior application (37 0	CFR 1.63 (d))	13. Prelimina	ry Amendment					
	(for a continuation/divisional with I	Box 17 completed)		14. X Return Receipt Postcard (MPEP 503)					
i. [	DELETION OF INVENTOR(S		• - •	(Should be specifically itemized)					
	Signed statement attached deleting in named in the prior application, see 37		15. Certified Copy of Priority Document(s)  (if foreign priority is claimed)						
	1.63(d)(2) and 1.33(b).		16. Other: Check for 980.00						
6. App									
4= 14 0011									
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) Prior application information: Examiner Group / Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.									
		17. CORRESPO	NDENCE ADDRESS						
☑ Customer Number or Bar Code Label  (Insert Capture and the proof of a correspondence address below									
	Antoinette F. Konski	0228	136						
Name	Baker & McKenzie								
	660 Hansen Way	PATENT TRACEHARK	OFFICE						
Address									
City	Palo Alto State		California	Zip Code	94304				
Country	USA Telephone		(650) 856-2400 Fax (650) 856-9299						
Name (Pri	int/Type) Antoinette F. Kons	ski	Registration No. (Attorney/Agent) 34,202						
Signature ////////////////////////////////////		1	Date	May 30, 2001					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

EEE TOANGRAITTAL	Complete if Known			
FEE TRANSMITTAL	Application Number	Unassigned		
for FY 2001	Filing Date			
	First Named Inventor	Charles A. Nicolette		
Patent fees are subject to annual revision.	Examiner Name	Unassigned Unassigned		
	Group / Art Unit			
TOTAL AMOUNT OF PAYMENT (\$) 980	Attorney Docket No.	126881209900		

TOTAL AMOUNT OF TATMENT (4) 300					Altomey Bocket No.						
METHOD OF PAYMENT (check one)					FEE CALCULATION (continued)						
1. Denosit	The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:  Deposit		3. ADD	3. ADDITIONAL FEES Large Small Entity Entity Fee		Fee Description	Fee				
Account 50-0974 Number				Code	(\$)	Code	(\$)	•	Paid		
		·			105 127	130 50	205 227	65 25	Surcharge - late filing fee or oath		
						127 .	30	221	25	Surcharge - late provisional filing fee or cover sheet.	
Deposit Account		Baker & Me	cKenzie			139	130	139	130	Non-English specification	
Name						147	2,520	147	2,520	For filing a request for reexamination	
Charge Any Additional Fee Required     Under 37 CFR 1.16 and 1.17						112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
Applicant claims small entity status. See 37 CFR 1.27						113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
2. A Payment Enclosed:						115	110	215	55	Extension for reply within first month	
☑ Check   Credit card   Money   Other Order					116	390	216	195	Extension for reply within second month		
FEE CALCULATION						117	890	217	445	Extension for reply within third month	
BASIC FILING FEE					118	1,390	218	695	Extension for reply within fourth month		
T	ntity S		<i>*</i>			128	1,890	228	945	Extension for reply within fifth month	
		ee Fee ode (\$)	Fee Description	1 Fee Paid		119	310	219	155	Notice of Appeal	<b></b>
•		01 355	Utility filing fee	710	7	120 121	310 270	220 221	155 135	Filing a brief in support of an appeal  Request for oral hearing	<b></b>
106 3	20 2	06 160 07 245	Design filing fee			138	1,510	138	1,510	Petition to institute a public use proceeding	
		08 355	Reissue filing fee	e	┪	140	110	240	55	Petition to revive – unavoidable	
		14 75	Provisional filling		1	141	1,240	241	620	Petition to revive – unintentional	
					_	142	1,240	242	620	Utility issue fee (or reissue)	
		SUBTO	TAL (1)	(\$) 710	J	143	440	243	220	Design issue fee	
2. EXTRA	CLAIM	FFFS				144	600	244	300	Plant issue fee	
2. 2	<b>VEAIII</b>		Extra F	ee from Fee		122	130	122	130	Petitions to the Commissioner	
Total Claims	13	-20**	Claims b	elow Paid = 0	]	123	130	123	130	Petitions related to provisional applications	
Independent Claims	3	-3**	= 0 x	= 0		126	180	126	180	Submission of Information Disclosure Stmt	
Multiple Dependent	1	- <del></del>	×[	270 = 270	j	581	40	581	40	Recording each patent assignment per property (times number of properties)	
Large Fee	Entity Fee	Fee F	ntity ee Fee Descript	tion		146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code 103	( <b>\$</b> ) 18	Code (\$	•)			149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
102	80	202 4	•	claims in excess of 3		179	710	279	355	Request for Continued Examination (RCE)	
104	270	204 1		ndent claim, if not paid		169	900	169	900	Request for expedited examination	<u> </u>
109	80	209 4	original paten			169	900	109	900	of a design application	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent					Other fee (specify) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0						
SUBTOTAL (2) (\$) 270											
**or number previously paid, if greater; For Reissues, see above											
""or numbe	n previou	siy paid, if gre	ater, FOR REISSUES, SE	es above		1					

SUBMITTED BY Complete (if applicable)								
Name (Print/Type)	Aptojnetje F. Konski	Registration No. Attorney/Agent)	34,202	Telephone	(650) 856-2400			
Signature	MINNING -	Maski		Date	May 30, 2001			

WKKNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

. Oseroseine and